IDEAYA Biosciences (IDEAYA Biosciences) Price-to-Free-Cash-Flow

: N/A (As of Today)

View and export this data going back to 2019. Start your Free Trial

As of today (2024-04-19), IDEAYA Biosciences's share price is $37.13. IDEAYA Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.08. Hence, IDEAYA Biosciences's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for IDEAYA Biosciences's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 7 years, IDEAYA Biosciences's highest Price-to-Free-Cash-Flow Ratio was 14.29. The lowest was 7.52. And the median was 11.55.

IDYA's Price-to-Free-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 29.77
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

IDEAYA Biosciences's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.38. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-2.08.

During the past 7 years, IDEAYA Biosciences's highest 3-Year average Free Cash Flow per Share Growth Rate was 12.40% per year. The lowest was 7.00% per year. And the median was 9.70% per year.

IDEAYA Biosciences Price-to-Free-Cash-Flow Historical Data

The historical data trend for IDEAYA Biosciences's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => 6.29 [4] => - [5] => - [6] => - )

IDEAYA Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Free-Cash-Flow

6.29

IDEAYA Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Free-Cash-Flow																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, IDEAYA Biosciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDEAYA Biosciences Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where IDEAYA Biosciences's Price-to-Free-Cash-Flow falls into.

IDEAYA Biosciences Price-to-Free-Cash-Flow Calculation

IDEAYA Biosciences's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio	=	Share Price	/	Free Cash Flow per Share (TTM)
	=	37.13	/	-2.076
	=	N/A

IDEAYA Biosciences's Share Price of today is $37.13.
IDEAYA Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.08.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio

Market Cap

Free Cash Flow

IDEAYA Biosciences (NAS:IDYA) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.

Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.

IDEAYA Biosciences Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of IDEAYA Biosciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

IDEAYA Biosciences (IDEAYA Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (NAS:IDYA) » Definitions » Price-to-Free-Cash-Flow

Comparable Companies

Traded in Other Exchanges

30J:Germany 30J:Germany

Address

7000 Shoreline Court, Suite 350, South San Francisco, CA, USA, 94080

Website

https://www.ideayabio.com

IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Executives

Yujiro S Hata	director, officer: President and CEO	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Briseno Andres Ruiz	officer: See Remarks	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Jason Throne	officer: VP, General Counsel	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Paul A. Stone	officer: SVP, General Counsel	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Darrin Beaupre	officer: SVP, Chief Medical Officer	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Michael Anthony White	officer: SVP, Chief Scientific Officer	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Michael P. Dillon	officer: SVP, Chief Scientific Officer	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Susan L. Kelley	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Mark Lackner	officer: SVP, Head of Biology	C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Andrew J. Schwab	10 percent owner, Former 10% holder	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
John D Diekman	10 percent owner, Former 10% holder	C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Scott M Rocklage	10 percent owner, Former 10% holder	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Iv, L.p.	10 percent owner, Former 10% holder	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107